01 Apr 2019 --- Sustainable ingredients company Amyris has reported on its first milestone for its US$300 million cannabinoid (CBD) collaboration with LAVVAN, earning its first payment of US$10 million. The companies entered into a partnership for the multi-million dollar development of a fermented CBD ingredient in February. The previously undisclosed partner, LAVVAN, is a newly-formed company backed by players from across the pharmaceutical, cannabis and financial sectors, which intends to bring the first fermentation-derived CBD products to market.
